Daewoong Pharmaceutical's botulinum toxin 'Nabota' continued its upward sales trend. The company's quarterly revenue exceeded KRW 50 billion for the first time, led by the company’s growth in overseas markets. Nabota’s share of Daewoong's specialty drug sales reached nearly 25 percent, driving the company's performance.

According to Daewoong Pharmaceutical on the 12th, Nabota generated sales of KRW 53.1 billion in Q2, up 62.4% year-on-year. This is the first time since its launch that the drug’s quarterly sales exceeded KRW 50 billion, surpassing the previous record of KRW 42.6 billion set in Q1 last year in less than a year. Nabota’s sales increased 74.7% in 2 years, compared to sales of KRW 30.4 bill